Fig. 5: Co-treatment with BEZ235 and TST synergistically inhibited breast cancer cell proliferation. | Cell Death & Disease

Fig. 5: Co-treatment with BEZ235 and TST synergistically inhibited breast cancer cell proliferation.

From: HDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation

Fig. 5

a T47D and b BT474 cells were treated with BEZ235 and TST for indicated times. Viable cells were measured by MTT assays. c T47D and d BT474 cells were treated with BEZ235 and TST for 24 h. The cells were then cultured for 2 weeks and the colonies were photographed. **P < 0.01, ***P < 0.001 versus control group. Data shown are mean ± SEM of at least three independent experiments

Back to article page